Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (12)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  3. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701

2023

  1. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

2022

  1. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort

    Neuro-oncology, Vol. 24, Núm. 10, pp. 1726-1735

  2. SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

    Frontiers in Pharmacology, Vol. 13

2021

  1. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

2020

  1. Epigenetic SmAd3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma

    Cancer Research, Vol. 80, Núm. 2, pp. 276-290

2018

  1. LncRNA-OIS1 regulates DPP4 activation to modulate senescence induced by RAS

    Nucleic Acids Research, Vol. 46, Núm. 8, pp. 4213-4227

  2. Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

    Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174

2016

  1. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

    Oncotarget, Vol. 7, Núm. 25, pp. 37407-37419

2015

  1. Evolving synergistic combinations of targeted immunotherapies to combat cancer

    Nature Reviews Cancer, Vol. 15, Núm. 8, pp. 457-472